Litcius/Paper detail

Subcutaneous versus intravenous nivolumab for renal cell carcinoma

Laurence Albigès, María T. Bourlon, Matías Chacón, Hernán Cutuli, Yamil Alonso Lopez Chuken, Bogdan Żurawski, José Maurício Mota, Ignacio Magrí, Mauricio Burotto, Murilo Luz, Juliana De Menezes, Eduardo Patricio Yanez Ruiz, Simon Fu, Martin Eduardo Richardet, Begoña P. Valderrama, Marco Maruzzo, Sergio Bracarda, Mary Alice B. Breckenridge, Heather Vezina, Darshana Rathod, Zhuoxin Yu, Yingchao Zhao, Matthew Dixon, Deepak Perumal, Shaji George

2024Annals of Oncology21 citationsDOI

Topics & Concepts

MedicineNivolumabRenal cell carcinomaOncologyCarcinomaInternal medicineUrologyImmunotherapyCancerCancer Immunotherapy and BiomarkersRenal cell carcinoma treatmentInflammatory Biomarkers in Disease Prognosis